Radiation Therapy for Osteosarcoma

 

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells. It can be given internally or externally:

  • External beam radiation therapy (EBRT) - Radiation from a high-energy x-ray machine (linear accelerator) outside the body is focused on the cancer cells. EBRT can harm both the cancer cells and nearby healthy tissue. Most people are treated with EBRT for a few minutes 5 days a week for several weeks as an outpatient. EBRT is the most common kind of radiation therapy for osteosarcoma.
  • Bone-seeking isotopes - A bone-seeking radioactive chemical, such as samarium-153, is injected into a vein. The chemical attaches to active areas of bone formation, including osteosarcoma. This treatment is useful for treating advanced disease and reducing pain.
  • Internal radiation therapy (brachytherapy or interstitial radiation therapy) - Small pellets (or “seeds”) that contain radioactive materials are placed in your body in or near the tumor. The radioactive pellets release their radiation slowly over time. Brachytherapy lets the doctor use a higher dose of radiation than EBRT.

It is difficult to kill osteosarcoma cells with radiation, so radiation therapy is not usually used to treat the disease. However, it can be useful for patients with tumors that cannot be completely removed by surgery, such as tumors in the pelvic or facial bones. In these cases, the surgeon removes as much of the tumor as possible and then radiation is used to kill the cancer that is left. Radiation therapy is also useful for treating certain symptoms, such as pain and swelling, if the cancer has come back (recurred) after treatment. 

This content has been reviewed and approved by Myo Thant, MD. 

This content was last modified on October 10, 2007 .
Latest Cancer News
ACS Guidelines for Breast Screening with MRI May Be Excluding Some High-risk Women

January 6, 2009 — The American Cancer Society (ACS) has developed a set of guidelines to recommend which high-risk women need to undergo screening with breast magnetic resonance imaging (MRI); however, these guidelines may unwittingly exclude some women who are at a high risk of carrying the BRCA mutation yet still don’t meet the limitations set by the ACS. The results of this study were published in the journal Cancer.

Colonoscopy Fails to Identify Many Colorectal Cancers

January 6, 2009 — Colonoscopy, a standard screening method for colorectal cancer, misses the majority of cancers on the right side of the colon and about one-third of cancers on the left side of the colon, according to the results of a study published in the Annals of Internal Medicine. The researchers estimated that the screening method may reduce colorectal cancer mortality by 60-70%, rather than 90% as previously estimated.

High-dose Faslodex® Improves Time to Progression Compared with Arimidex® as Initial Therapy in Advanced Breast Cancer

January 6, 2009 — Researchers affiliated with an international trial have reported that high-dose Faslodex® (fulvestrant) significantly improves time to cancer progression compared with Arimidex® (anastrozole) as initial therapy for hormone-positive, advanced breast cancer. These results were recently presented at the 2008 annual San Antonio Breast Cancer Symposium December 10-14, 2008.

Select news items provided by Reuters Health